Physician profile
Bilal Farooqi
NPI 1467891333
$5,563.06
in general payments reported to CMS, 2019-2025
43 companies · $470 in 2025
The $470 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $2,515 · 2021: $75.04 · 2022: $703 · 2023: $153 · 2024: $532 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.93 |
| Education | $141.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,896.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $814.01 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Incyte Corporation | $243.41 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $218.19 | 2019-2025 | |
| Astellas Pharma US INC | $209.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $201.69 | 2019-2025 | Keytruda, Lynparza |
| Lilly USA, LLC | $184.28 | 2019-2024 | |
| Beone Medicines USA, INC. | $143.18 | 2025 | Tevimbra |
| Daiichi Sankyo INC. | $128.01 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $125.00 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Clovis Oncology, INC. | $115.52 | 2019 | |
| Amgen INC. | $109.12 | 2019-2020 | |
| Pfizer INC. | $105.27 | 2019-2022 | |
| Beigene USA, INC. | $96.01 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $80.07 | 2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Farooqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.